Michelle Lally

Followers

Following

Co-authors

Public Views

Betsy Crane

Widener University

Victoria Clarke

University of the West of England

Morten Tønnessen

University of Stavanger

JoAnn Manson

Harvard University

Jennifer Unger

University of Southern California

Gisela van Rensburg

UNISA

Alan McKee

University of Technology Sydney

Bonnie Spring

Northwestern University

Jeanette Maritz

University of South Africa

Daniel Egah

University Of Jos Nigeria

Interests

Uploads

Papers by Michelle Lally

Hepatitis B and C in the context of HIV disease: implications for incarcerated populations

PubMed, Oct 1, 1999

HIV-infected inmates are often co-infected with hepatitis B and/or hepatitis C virus. To describe... more HIV-infected inmates are often co-infected with hepatitis B and/or hepatitis C virus. To describe the burden of HIV in the incarcerated population today, one must consider the impact of co-infection. HIV may dramatically modify the course of viral hepatitis infection, especially chronic hepatitis C. The converse is uncertain: chronic hepatitis does not seem to accelerate HIV disease progression. In this article, we offer guidelines for selecting appropriate candidates for treatment among co-infected inmates.

Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test

Journal of Clinical Microbiology, May 1, 2019

The Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test, v2.0 (the CAP/ CTM assay), was used to quantif... more The Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test, v2.0 (the CAP/ CTM assay), was used to quantify cell-associated HIV-1 (CAH) nucleic acid in peripheral blood mononuclear cells (PBMC) from well-characterized clinical specimens from HIV-1-infected individuals on antiretroviral therapy (ART). Chronically infected individuals on ART with no detectable plasma HIV-1 RNA demonstrated average CAH burdens of 3.2 HIV-1 log 10 copies/million cells. Assay sensitivity and specificity were 98.9% and 100%, respectively, with the positive and negative predictive values being 100% and 98.6%, respectively. The CAH burden was also measured at weeks 0, 1, 2, 8, and 60 in 37 participants (RV254/SEARCH010, Bangkok, Thailand) stratified by Fiebig stage (Fiebig stage I [FI] to FVI) at ART initiation. Prior to ART initiation, the average CAH burden was 1.4, 4.1, and 3.6 log 10 copies/million PBMCs for individuals who initiated ART at FI, FII, and FIII to FVI, respectively. Initiation of ART resulted in a rapid decline of CAH in all individuals, with the greatest decrease being observed in individuals who initiated ART at FI to FIII. By week 60, 100% (FI), 71.8% (FII/FIII), and 20.5% (FIV to FVI) of samples from individuals initiating treatment were at or near the limit of quantitation. Residual CAH was detectable at 60 weeks in most individuals who initiated ART at later stages (FIV to FVI) and averaged 1.9 Ϯ 0.7 log 10 copies/ million PBMCs. The modified Roche CAP/CTM assay provides a convenient, standardized approach to measure residual HIV in blood and may be useful for monitoring patients under therapy or those participating in HIV remission studies.

Directory

Michelle Lally

Uploads

Papers by Michelle Lally

Log In